Read by QxMD icon Read

European Journal of Cancer

Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, Peter Malfertheiner, Jean Francois Seitz, Joon Oh Park, Baek-Yeol Ryoo, Chia-Jui Yen, Masatoshi Kudo, Ronnie Poon, Davide Pastorelli, Jean-Frederic Blanc, Hyun Cheol Chung, Ari D Baron, Takuji Okusaka, L Bowman, Zhanglin Lin Cui, Allicia C Girvan, Paolo B Abada, Ling Yang, Andrew X Zhu
No abstract text is available yet for this article.
June 30, 2018: European Journal of Cancer
Evelyne M J Meys, Lara S Jeelof, Bram L T Ramaekers, Carmen D Dirksen, Loes F S Kooreman, Brigitte F M Slangen, Roy F P M Kruitwagen, Toon Van Gorp
The Risk of Malignancy Index (RMI) is commonly used to diagnose adnexal masses. The aim of the present study was to determine the cost-effectiveness of the RMI compared with subjective assessment (SA) by an expert and the following novel ultrasound models: Cost-effectiveness and budget impact analyses were performed from a societal perspective. A decision tree was constructed, and short-term costs and effects were examined in women with adnexal masses. Sensitivity, specificity and the costs of diagnostic strategies were incorporated...
June 25, 2018: European Journal of Cancer
H G Smith, M J Wilkinson, M J F Smith, D C Strauss, A J Hayes
BACKGROUND: Isolated limb perfusion (ILP) is a well-established treatment for patients with advanced extremity malignancies unsuitable for limb-conserving surgery. However, little is known about the outcomes of this treatment in elderly patients. We sought to determine the effects of age on the tolerability and efficacy of ILP for advanced extremity malignancy. PATIENTS AND METHODS: Patients undergoing ILP at our institution between January 2005 and January 2018 were identified from a prospectively maintained database...
June 22, 2018: European Journal of Cancer
Morten Aa Petersen, Neil K Aaronson, Juan I Arraras, Wei-Chu Chie, Thierry Conroy, Anna Costantini, Linda Dirven, Peter Fayers, Eva-Maria Gamper, Johannes M Giesinger, Esther J J Habets, Eva Hammerlid, Jorunn Helbostad, Marianne J Hjermstad, Bernhard Holzner, Colin Johnson, Georg Kemmler, Madeleine T King, Stein Kaasa, Jon H Loge, Jaap C Reijneveld, Susanne Singer, Martin J B Taphoorn, Lise H Thamsborg, Krzysztof A Tomaszewski, Galina Velikova, Irma M Verdonck-de Leeuw, Teresa Young, Mogens Groenvold
BACKGROUND: To optimise measurement precision, relevance to patients and flexibility, patient-reported outcome measures (PROMs) should ideally be adapted to the individual patient/study while retaining direct comparability of scores across patients/studies. This is achievable using item banks and computerised adaptive tests (CATs). The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) is one of the most widely used PROMs in cancer research and clinical practice...
June 21, 2018: European Journal of Cancer
Kaitlyn K H Goey, Halfdan Sørbye, Bengt Glimelius, Richard A Adams, Thierry André, Dirk Arnold, Jordan D Berlin, György Bodoky, Aimery de Gramont, Eduardo Díaz-Rubio, Cathy Eng, Alfredo Falcone, Axel Grothey, Volker Heinemann, Howard S Hochster, Richard S Kaplan, Scott Kopetz, Roberto Labianca, Christopher H Lieu, Neal J Meropol, Timothy J Price, Richard L Schilsky, Hans-Joachim Schmoll, Einat Shacham-Shmueli, Qian Shi, Alberto F Sobrero, John Souglakos, Eric Van Cutsem, John Zalcberg, Martijn G H van Oijen, Cornelis J A Punt, Miriam Koopman
BACKGROUND: Patient characteristics and stratification factors are key features influencing trial outcomes. However, there is substantial heterogeneity in reporting of patient characteristics and use of stratification factors in phase 3 trials investigating systemic treatment of metastatic colorectal cancer (mCRC). We aimed to develop a minimum set of essential baseline characteristics and stratification factors to include in such trials. METHODS: We performed a modified, two-round Delphi survey among international experts with wide experience in the conduct and methodology of phase 3 trials of systemic treatment of mCRC...
June 21, 2018: European Journal of Cancer
Lucas Moreno, Michela Casanova, Julia C Chisholm, Pablo Berlanga, Pascal B Chastagner, Sylvain Baruchel, Loredana Amoroso, Soledad Gallego Melcón, Nicolas U Gerber, Gianni Bisogno, Franca Fagioli, Birgit Geoerger, Julia L Glade Bender, Isabelle Aerts, Christophe Bergeron, Pooja Hingorani, Ileana Elias, Mathew Simcock, Stefano Ferrara, Yvan Le Bruchec, Ruta Slepetis, Nianhang Chen, Gilles Vassal
BACKGROUND: nab-Paclitaxel has demonstrated efficacy in adults with solid tumours and preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in paediatric patients with recurrent/refractory solid tumours treated with nab-paclitaxel are reported. PATIENTS AND METHODS: Patients with recurrent/refractory extracranial solid tumours received nab-paclitaxel on days 1, 8 and 15 every 4 weeks at 120, 150, 180, 210, 240, or 270 mg/m2 (rolling-6 dose-escalation) to establish the maximum tolerated dose (MTD) and recommended phase II dose (RP2D)...
June 21, 2018: European Journal of Cancer
Ugur Sahin, Martin Schuler, Heike Richly, Stefan Bauer, Anna Krilova, Tobias Dechow, Markus Jerling, Magdalena Utsch, Christoph Rohde, Karl Dhaene, Christoph Huber, Özlem Türeci
INTRODUCTION: IMAB362 (Zolbetuximab) is a chimeric monoclonal antibody that binds to Claudin-18.2, a target antigen specific to cancer cells. In vitro, IMAB362 mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity; thus, IMAB362 may serve as a potent, targeted immunotherapeutic agent. METHODS: This first-in-human phase I study enroled adult patients (N = 15) with advanced gastric or gastro-oesophageal junction cancer into five sequential single dose-escalation cohorts (33, 100, 300, 600, and 1000 mg/m2 ) following a 3 + 3 design...
June 21, 2018: European Journal of Cancer
Xinan Sheng, Dengfeng Cao, Jianlin Yuan, Fangjian Zhou, Qiang Wei, Xiaodong Xie, Chuanliang Cui, Zhihong Chi, Lu Si, Siming Li, Lili Mao, Bin Lian, Bixia Tang, Xieqiao Yan, Xuan Wang, Yan Kong, Jie Dai, Xue Bai, Li Zhou, Jun Guo
BACKGROUND: Collecting duct carcinoma (CDC) is a rare type of renal cancer with a poor prognosis. As there are no standard guidelines for the management of metastatic CDC (mCDC), we evaluated the efficacy and safety of combined therapies of sorafenib, gemcitabine, plus cisplatin in patients with mCDC. MATERIALS AND METHODS: A prospective, multicentre, single-arm, open-label, phase 2 trial ( identifier NCT01762150) that enrolled 26 mCDC patients with no prior systemic chemotherapy...
June 19, 2018: European Journal of Cancer
Laura Milsch, Anja Gesierich, Sophia Kreft, Elisabeth Livingstone, Lisa Zimmer, Matthias Goebeler, Dirk Schadendorf, Bastian Schilling
OBJECTIVES: Immune-checkpoint blockers (ICBs) significantly prolong overall survival (OS) in patients with advanced melanoma. Limited data are available on the efficacy and clinical benefit in patients with melanoma brain metastases (MBMs). The aim of this study was to determine whether ICB is active in an unselected cohort treated of patients with known brain metastases and if disease control correlates with the survival. METHODS: A total of 385 patients with metastatic malignant melanoma treated with ICB as monotherapy between 2005 and 2017 in two tertiary referral centres were included...
June 12, 2018: European Journal of Cancer
Paolo Vineis, Daniela Fecht
The proportion of total deaths attributable to environmental factors is estimated to be 23% of global deaths and 22% of global disability-adjusted life years (DALYs) according to one review. These estimates encompass all environmental agents including infectious agents but excluding behavioural factors. The authors of the review also estimated that 16% (95% CI: 7-41%) of cancer deaths are attributable to environmental risk factors (and 36% [95% CI: 17-52%] for lung cancer). In this article, we focus on the reasons why epidemiology is often unable to account for the whole burden of environmental carcinogens...
June 11, 2018: European Journal of Cancer
Guanhua Rao, In-Kyu Kim, Fabio Conforti, Jing Liu, Yu-Wen Zhang, Giuseppe Giaccone
PURPOSE: Oncogenic KRAS mutations occur frequently in solid tumours, but no clinically applicable targeted strategy is yet available for treating human cancers with mutant KRAS. Here we aimed to identify a strategy for the treatment of KRAS-driven cancers. EXPERIMENTAL DESIGN: Cell viability and colony forming assays were used to assess the in vitro effect of dasatinib and trametinib as single agents or in combination. Western blot was used to analyse the phosphorylated protein and total protein levels...
June 11, 2018: European Journal of Cancer
Thomas Brodowicz, Olivier Mir, Jennifer Wallet, Antoine Italiano, Jean-Yves Blay, François Bertucci, Wolfgang Eisterer, Christine Chevreau, Sophie Piperno-Neumann, Emmanuelle Bompas, Thomas Ryckewaert, Bernadette Liegl-Antzwager, Julien Thery, Nicolas Penel, Axel Le Cesne, Marie-Cécile Le Deley
INTRODUCTION: The placebo-controlled phase-2 REGOSARC trial demonstrated the efficacy of regorafenib in patients with leiomyosarcoma, synovial sarcoma and other non-adipocytic sarcoma but not in liposarcoma. Patients initially allocated to placebo were allowed to receive regorafenib after progression. We report here an updated analysis of the trial including evaluation of regorafenib activity after cross-over. METHODS: From June 2013 to December 2014, 139 patients were enrolled in the non-adipocytic sarcoma cohorts...
June 11, 2018: European Journal of Cancer
C R Lindsay, M Jamal-Hanjani, M Forster, F Blackhall
Despite being the most frequent gain-of-function genetic alteration in human cancer, KRAS mutation has to date offered only limited potential as a prognostic and predictive biomarker. Results from the phase III SELECT-1 trial in non-small cell lung cancer (NSCLC) recently added to a number of historical and more contemporary disappointments in targeting KRAS mutant disease, including farnesyl transferase inhibition and synthetic lethality partners such as STK33. This narrative review uses the context of these previous failures to demonstrate how the knowledge gained from these experiences can be used as a platform for exciting advances in NSCLC on the horizon...
June 9, 2018: European Journal of Cancer
Stefania Gori, Fabio Puglisi, Michela Cinquini, Giovanni Pappagallo, Antonio Frassoldati, Laura Biganzoli, Laura Cortesi, Alba Fiorentino, Catia Angiolini, Corrado Tinterri, Andrea De Censi, Alessia Levaggi, Lucia Del Mastro
Premenopausal women with hormone receptor-positive early breast cancer are candidates for adjuvant endocrine therapy, as recommended by the major international guidelines. To date, adjuvant endocrine options for premenopausal women include tamoxifen with or without ovarian function suppression (OFS) or an aromatase inhibitor with OFS. Multiple strategies for endocrine treatment of premenopausal women with hormone-responsive breast cancer have been assessed, and the results of randomised clinical trials have been reported over the last years...
June 7, 2018: European Journal of Cancer
M G M Derks, E Bastiaannet, W van de Water, N A de Glas, C Seynaeve, H Putter, J W R Nortier, D Rea, A Hasenburg, C Markopoulos, L Y Dirix, J E A Portielje, C J H van de Velde, G J Liefers
AIM: Due to increasing life expectancy, patients with breast cancer remain at risk of dying due to breast cancer over a long time. This study aims to assess the impact of age on breast cancer mortality and other cause mortality 10 years after diagnosis. METHODS: Postmenopausal patients with hormone-receptor positive breast cancer were included in the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial between 2001 and 2006. Age at diagnosis was categorised as <65 years (n = 3369), 65-74 years (n = 1896) and ≥75 years (n = 854)...
June 6, 2018: European Journal of Cancer
Therese M-L Andersson, Gerda Engholm, Eero Pukkala, Magnus Stenbeck, Laufey Tryggvadottir, Hans Storm, Elisabete Weiderpass
BACKGROUND: Alcohol consumption is an important and preventable cause of cancer. The aim of this study was to quantify the proportion of the cancer burden in the Nordic countries linked to alcohol and estimate the potential for cancer prevention by changes in alcohol consumption. METHODS: Using the Prevent macro-simulation model, the number of cancer cases in the Nordic countries over a 30-year period (2016-2045) was modelled for six sites, under different scenarios of changing alcohol consumption, and compared to the projected number of cases if constant alcohol consumption prevailed...
May 5, 2018: European Journal of Cancer
Lion Shahab, Jennifer A McGowan, Jo Waller, Samuel G Smith
BACKGROUND: Literature on population awareness about actual causes of cancer is growing but comparatively little is known about the prevalence of people's belief concerning mythical causes of cancer. This study aimed to estimate the prevalence of these beliefs and their association with socio-demographic characteristics and health behaviours. METHODS: A survey containing validated measures of beliefs about actual and mythical cancer causes and health behaviours (smoking, alcohol consumption, physical activity, fruit and vegetable consumption, overweight) was administered to a representative English population sample (N = 1330)...
April 26, 2018: European Journal of Cancer
Maja Bech Juul, Pernille Hammershoej Jensen, Henriette Engberg, Sonja Wehberg, Andriette Dessau-Arp, Donika Haziri, Helene Bjoerg Kristensen, Joachim Baech, Lene Schurmann, Michael Roost Clausen, Rebecca Valentin, Lene Meldgaard Knudsen, Lars Munksgaard, Tarec Christoffer El-Galaly, Henrik Frederiksen, Thomas Stauffer Larsen
BACKGROUND: Optimal treatment strategy for the oldest patients with diffuse large B-cell lymphoma (DLBCL) remains controversial, as this group often is precluded from clinical trials, and population-based studies are limited. METHODS: All Danish DLBCL-patients ≥75 years diagnosed from 2003 to 2012 were identified, using the Danish National Lymphoma Registry (LYFO). Information regarding baseline characteristics, treatment, comorbidities and outcomes was retrieved from LYFO, the Danish National health registries and medical records...
August 2018: European Journal of Cancer
Kirsten Sundby Hall, Øyvind S Bruland, Bodil Bjerkehagen, Olga Zaikova, Jacob Engellau, Oskar Hagberg, Lina Hansson, Hans Hagberg, Marie Ahlström, Heidi Knobel, Karin Papworth, Maja Zemmler, Dorota Goplen, Henrik C F Bauer, Mikael Eriksson
PURPOSE: To investigate the outcome following adjuvant doxorubicin and ifosfamide in a prospective non-randomised study based on a soft tissue sarcoma (STS) patient subgroup defined by specific morphological characteristics previously shown to be at a high-risk of metastatic relapse. The expected 5-year cumulative incidence of metastases in patients with this risk profile has previously been reported to be about 50% without adjuvant chemotherapy. METHODS: High-risk STS was defined as high-grade morphology (according to the Fédération Nationale des Centres de Lutte Contre le Cancer [FNCLCC] grade II-III) and either vascular invasion or at least two of the following criteria: tumour size ≥8...
August 2018: European Journal of Cancer
Sabine Tejpar, Pu Yan, Hubert Piessevaux, Daniel Dietrich, Peter Brauchli, Dirk Klingbiel, Roberto Fiocca, Mauro Delorenzi, Fred Bosman, Arnaud D Roth
PURPOSE: Irinotecan (CPT-11) in combination with 5-fluorouracil (5FU) is widely used in the treatment of colorectal cancer. We assessed potential clinical variables that may predict toxicity and more specifically the role of UGT1A1 polymorphisms associated with irinotecan toxicity. We used data from the PETACC3 trial, which randomised patients in adjuvant setting to 6 months of leucovorin (LV) and 5FU (LV5/FU2) or LV5/FU2 + irinotecan. PATIENTS AND METHODS: Clinical and toxicity data were available for 2982 patients, DNA was available for 1200 (40%) of these patients...
August 2018: European Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"